Fu‐Fei Hsu
Institute of Biomedical Sciences, Academia Sinica(TW)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, Monoclonal and Polyclonal Antibodies Research, Nanoparticle-Based Drug Delivery, RNA Interference and Gene Delivery, Nanoplatforms for cancer theranostics
Most-Cited Works
- → Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies(2019)439 cited
- → Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer(2020)252 cited
- → A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies(2022)153 cited
- → The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1(2007)108 cited
- → Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors(2017)81 cited
- → A multifunctional nanocarrier for efficient TRAIL‐based gene therapy against hepatocellular carcinoma with desmoplasia in mice(2017)51 cited
- → Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours(2021)46 cited
- → Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation(2018)44 cited
- → A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants(2022)43 cited
- → Dual-Functional Nanoparticles Targeting CXCR4 and Delivering Antiangiogenic siRNA Ameliorate Liver Fibrosis(2016)35 cited